References
- US FDA . Paving the way for personalized medicine ( 2013 ). www.fda.gov/downloads/ScienceResearch/SpecialTopics/PrecisionMedicine/UCM372421.pdf .
- US FDA . Table of pharmacogenomic biomarkers in drug labeling ( 2015 ). www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm .
- PMC More than 20 percent of the novel new drugs approved by FDA’s Center for Drug Evaluation and Research in 2014 are personalized medicines ( 2014 ). www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/2014-fda-approvals-personalized-medicine2.pdf .
- US FDA . Novel drug approvals for 2015 . www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm430302.htm .
- Engert A , BalduiniC , BrandAet al. The European Hematology Association Roadmap for European Hematology Research: a consensus document . Haematologica101 ( 2 ), 115 – 208 ( 2016 ).
- Nagalla S , BrayPF . Personalized medicine in thrombosis: back to the future . Blood127 ( 22 ), 2665 – 2671 ( 2016 ).
- Smith SA , FrenchT , HollingsworthSJ . The impact of germline mutations on targeted therapy . J. Pathol.232 ( 2 ), 230 – 243 ( 2014 ).
- Badalian-Very G . Personalized medicine in hematology – a landmark from bench to bed . Comput. Struct. Biotechnol. J.10 ( 17 ), 70 – 77 ( 2014 ).
- Hayes DF , SchottAF . Personalized medicine: genomics trials in oncology . Trans. Am. Clin. Climatol. Assoc.126 , 133 – 143 ( 2015 ).
- Kelley RK , Van BebberSL , PhillipsKA , VenookAP . Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer . J. Natl Compr. Canc. Netw.9 ( 1 ), 13 – 25 ( 2011 ).
- Evolution of Translational Omics: Lessons Learned and the Path Forward . MicheelCM , NassSJ , OmennGS ( Eds ). National Academies Press , Washington, DC, USA ( 2012 ).
- Wajcman H , MoradkhaniK . Abnormal haemoglobins: detection & characterization . Indian J. Med. Res.134 ( 4 ), 538 – 546 ( 2011 ).
- Locatelli F , KabbaraN , RuggeriAet al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling . Blood122 ( 6 ), 1072 – 1078 ( 2013 ).
- Cao A , GalanelloR . Beta-thalassemia . Genet. Med.12 ( 2 ), 61 – 76 ( 2010 ).
- Archer N , GalacterosF , BrugnaraC . 2015 clinical trials update in sickle cell anemia . Am. J. Hematol.90 ( 10 ), 934 – 950 ( 2015 ).
- Clinical trials database: NCT02140554 . https://clinicaltrials.gov/ct2/show/NCT02140554 .
- Clinical trials database: NCT02151526 . https://clinicaltrials.gov/ct2/show/NCT02151526 .
- Clinical trials database:NCT01745120 . https://clinicaltrials.gov/ct2/show/NCT01745120 .
- Miccio A , CesariR , LottiFet al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia . Proc. Natl Acad. Sci. USA105 ( 30 ), 10547 – 10552 ( 2008 ).
- Clinical trials database: NCT02453477 . https://clinicaltrials.gov/ct2/show/NCT02453477 .
- Clinical trials database: NCT02247843 . https://clinicaltrials.gov/ct2/show/NCT02247843 .
- Clinical trials database: NCT02186418 . https://clinicaltrials.gov/ct2/show/NCT02186418 .
- Rivella S . Beta-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies . Haematologica100 ( 4 ), 418 – 430 ( 2015 ).
- Negre O , EggimannAV , BeuzardYet al. Gene therapy of the beta-hemoglobinopathies by lentiviral transfer of the beta(A(T87Q))-globin gene . Hum. Gene Ther.27 ( 2 ), 148 – 165 ( 2016 ).
- Clinical trials database: NCT01639690 . https://clinicaltrials.gov/ct2/show/NCT01639690 .
- De Dreuzy E , BhukhaiK , LeboulchP , PayenE . Current and future alternative therapies for beta-thalassemia major . Biomed. J.39 ( 1 ), 24 – 38 ( 2016 ).
- Hoban MD , OrkinSH , BauerDE . Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease . Blood127 ( 7 ), 839 – 848 ( 2016 ).
- Akinsheye I , AlsultanA , SolovieffNet al. Fetal hemoglobin in sickle cell anemia . Blood118 ( 1 ), 19 – 27 ( 2011 ).
- Musallam KM , TaherAT , CappelliniMD , SankaranVG . Clinical experience with fetal hemoglobin induction therapy in patients with beta-thalassemia . Blood121 ( 12 ), 2199 – 2212 ; quiz 2372 ( 2013 ).
- Sankaran VG , MenneTF , XuJet al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A . Science322 ( 5909 ), 1839 – 1842 ( 2008 ).
- Canver MC , SmithEC , SherFet al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis . Nature527 ( 7577 ), 192 – 197 ( 2015 ).
- Masuda T , WangX , MaedaMet al. Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin . Science351 ( 6270 ), 285 – 289 ( 2016 ).
- Smith EC , OrkinSH . Hemoglobin genetics: recent contributions of GWAS and gene editing . Hum. Mol. Genet. doi:10.1093/hmg/ddw170 ( 2016 ) ( Epub ahead of print ).
- Peyvandi F , MannucciPM , ValsecchiC , PontiggiaS , FarinaC , RetziosAD . ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates . Am. J. Hematol.88 ( 10 ), 895 – 898 ( 2013 ).
- Scully M , BrownJ , PatelR , McdonaldV , BrownCJ , MachinS . Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link . J. Thromb. Haemost.8 ( 2 ), 257 – 262 ( 2010 ).
- Hanby HA , ZhengXL . Current status in diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura . Hereditary Genet.3 ( 1 ), e108 ( 2014 ).
- Clinical trials database: NCT01257269 . https://clinicaltrials.gov/ct2/show/study/NCT01257269 .
- Martino S , JammeM , DelignyCet al. Thrombotic thrombocytopenic purpura in black people: impact of ethnicity on survival and genetic risk factors . PLoS ONE11 ( 7 ), e0156679 ( 2016 ).
- Clinical trials database: NCT02216084 . https://clinicaltrials.gov/ct2/show/record/NCT02216084 .
- Seo JY , JangMA , KimHJ , LeeKO , KimSH , KimHJ . Sequence variation data of F8 and F9 genes in functionally validated control individuals: implications on the molecular diagnosis of hemophilia . Blood Res.48 ( 3 ), 206 – 210 ( 2013 ).
- James PD , GoodeveAC . von Willebrand disease . Genet. Med.13 ( 5 ), 365 – 376 ( 2011 ).
- Sagheer S , RodgersS , YacoubO , DauerR , McraeS , DuncanE . Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and HemosIL LIA assay with ristocetin cofactor assay by aggregometry . Haemophilia22 ( 3 ), e200 – e207 ( 2016 ).
- Bergmann AK , GraceRF , NeufeldEJ . Genetic studies in pediatric ITP: outlook, feasibility, and requirements . Ann. Hematol.89 ( Suppl. 1 ), S95 – S103 ( 2010 ).
- Palla R , PeyvandiF , ShapiroAD . Rare bleeding disorders: diagnosis and treatment . Blood125 ( 13 ), 2052 – 2061 ( 2015 ).
- Simeoni I , StephensJC , HuFet al. A comprehensive high-throughput sequencing test for the diagnosis of inherited bleeding, thrombotic and platelet disorders . Blood127 ( 23 ), 2791 – 2803 ( 2016 ).
- Martin K , KeyNS . How I treat patients with inherited bleeding disorders who need anticoagulant therapy . Blood128 ( 2 ), 178 – 184 ( 2016 ).
- Gill JC , CastamanG , WindygaJet al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease . Blood126 ( 17 ), 2038 – 2046 ( 2015 ).
- Taylor JA , Kruse-JarresR . A new era for hemophilia B treatment . Blood127 ( 14 ), 1734 – 1736 ( 2016 ).
- Uchida N , SambeT , YoneyamaKet al. A first-in-human Phase I study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects . Blood127 ( 13 ), 1633 – 1641 ( 2016 ).
- Herzog RW . Hemophilia gene therapy: caught between a cure and an immune response . Mol. Ther.23 ( 9 ), 1411 – 1412 ( 2015 ).
- George LA , FogartyPF . Gene therapy for hemophilia: past, present and future . Semin. Hematol.53 ( 1 ), 46 – 54 ( 2016 ).
- Monahan PE . Gene therapy in an era of emerging treatment options for hemophilia B . J. Thromb. Haemost.13 ( Suppl. 1 ), S151 – S160 ( 2015 ).
- Monahan PE , SunJ , GuiTet al. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial . Hum. Gene. Ther.26 ( 2 ), 69 – 81 ( 2015 ).
- Arruda VR , Samelson-JonesBJ . Obstacles and future of gene therapy for hemophilia . Expert Opin. Orphan Drugs3 ( 9 ), 997 – 1010 ( 2015 ).
- Park CY , KimDH , SonJSet al. Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9 . Cell Stem Cell17 ( 2 ), 213 – 220 ( 2015 ).
- Gorski MM , BligheK , LottaLAet al. Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients . Blood127 ( 23 ), 2924 – 2933 ( 2016 ).
- Eckhardt CL , Van VelzenAS , PetersMet al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A . Blood122 ( 11 ), 1954 – 1962 ( 2013 ).
- Gouw SC , van den BergHM , OldenburgJet al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis . Blood119 ( 12 ), 2922 – 2934 ( 2012 ).
- Lozier JN , RosenbergPS , GoedertJJ , MenasheI . A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A . Haemophilia17 ( 4 ), 641 – 649 ( 2011 ).
- Witmer C , YoungG . Factor VIII inhibitors in hemophilia A: rationale and latest evidence . Ther. Adv. Hematol.4 ( 1 ), 59 – 72 ( 2013 ).
- Miller CH , BensonJ , EllingsenDet al. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity . Haemophilia18 ( 3 ), 375 – 382 ( 2012 ).
- Daien CI , MorelJ . Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine . Mediators Inflamm.2014 ( 386148 ), ( 2014 ).
- Abshire T , Cox-GillJ , KemptonCLet al. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network . J. Thromb. Haemost.13 ( 9 ), 1585 – 1589 ( 2015 ).
- Collins PW . Personalized prophylaxis . Haemophilia18 ( Suppl. 4 ), S131 – S135 ( 2012 ).
- The White House . Remarks of President Barack Obama – as prepared for Delivery State of the Union Address . www.whitehouse.gov/the-press-office/2015/01/20/remarks-president-barack-obama-prepared-delivery-state-union-address .
- Hamburg MA , CollinsFS . The path to personalized medicine . N. Engl. J Med.363 ( 4 ), 301 – 304 ( 2010 ).
- Kinkorova J . Biobanks in the era of personalized medicine: objectives, challenges, and innovation: overview . EPMA J.7 ( 4 ), ( 2015 ).
- NIH . Accelerating medicines partnership . http://nih.gov/science/amp/index.htm .
- Personalized Medicine Coaliton . Public Opinion Survey . http://personalizedmedicinecoalition.org/Resources/PMC_Public_Opinion_Survey .
- Zhang L , HongH . Genomic discoveries and personalized medicine in neurological diseases . Pharmaceutics7 ( 4 ), 542 – 553 ( 2015 ).